Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cartesian Therapeutics, Inc. Director's Dealing 2017

Apr 4, 2017

33483_dirs_2017-04-04_35b66c1a-f504-43f8-b723-e63f44ee50f2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2017-03-27

Reporting Person: BARABE TIMOTHY C (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-03-27 Common Stock M 2492 $11.00 Acquired 2492 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-03-27 Stock Option (Right to Buy) $11.00 M 2492 Disposed 2026-07-28 Common Stock (2492) Direct

Footnotes

F1: The option vests in thirty-six (36) substantially equal monthly installments over three years following the date of grant.